Sutro Biopharma, Inc.
STRO · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $1,414 | $2,581 | $4,100 | $6,863 |
| - Cash | $190 | $69 | $47 | $30 |
| + Debt | $204 | $34 | $55 | $57 |
| Enterprise Value | $1,427 | $2,545 | $4,107 | $6,889 |
| Revenue | $62 | $154 | $68 | $62 |
| % Growth | -59.6% | 126.8% | 9.5% | – |
| Gross Profit | $55 | $147 | $59 | $52 |
| % Margin | 88.4% | 95.6% | 87.8% | 84.2% |
| EBITDA | -$180 | -$68 | -$105 | -$98 |
| % Margin | -290.9% | -44.2% | -155% | -157.7% |
| Net Income | -$227 | -$107 | -$119 | -$106 |
| % Margin | -366.6% | -69.5% | -175.9% | -170.6% |
| EPS Diluted | -29.6 | -17.8 | -23.5 | -22.9 |
| % Growth | -66.3% | 24.3% | -2.6% | – |
| Operating Cash Flow | -$192 | -$112 | $4 | -$82 |
| Capital Expenditures | -$3 | -$4 | -$8 | -$15 |
| Free Cash Flow | -$195 | -$116 | -$4 | -$97 |